Study on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) causing Community Acquired Pneumonia (CAP) in Residents aged 18 Years or Older in Spain

Trial Profile

Study on Distribution of Streptococcus Pneumonia Serotypes (PCV13 and PCV7) causing Community Acquired Pneumonia (CAP) in Residents aged 18 Years or Older in Spain

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
  • Indications Community-acquired pneumonia
  • Focus Therapeutic Use
  • Acronyms CAPA
  • Sponsors Pfizer
  • Most Recent Events

    • 12 May 2017 New trial record
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top